← All trials
NCT03681548
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 29, 2018
- Primary completion
- Mar 31, 2019
- Completion date
- May 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 52
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ayana Pharma Ltd.,Lead sponsor
- Lambda Therapeutic Research LtdStudy director
- Lambda Therapeutic Research LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.